A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.
Multiple Myeloma
DRUG: Clofarabine
Overall response rate (CR+PR), Every 3 months
Time to response, Every 3 months|Safety and tolerability of clofarabine, 30 days after last treatment|Duration of response, Every 3 months|Time to progression, Every 3 months
To determine the time to response, duration of response, and time to progression of patients treated with clofarabine.

To determine the safety and tolerability of clofarabine in these patients.